培美曲塞与吉西他滨治疗晚期非小细胞肺癌的效果对比  

Efficacy comparison of pemetrexed and gemcitabine in treatment of advanced non small cell lung cancer

作　　者：林长裕 杨锭洪 李伟健[1] 

机构地区：[1]广东省普宁市人民医院肿瘤内科,广东普宁515300

出　　处：《中国当代医药》2015年第5期131-133,共3页China Modern Medicine

摘　　要：目的比较培美曲塞与吉西他滨分别联合奈达铂治疗晚期非小细胞癌的临床效果。方法选取本院2011年7月～2013年8月收治的100例肺腺癌患者为研究对象,抽签随机分为观察组与对照组各50例,观察组给予培美曲塞＋奈达铂治疗,对照组给予吉西他滨＋奈达铂治疗,比较两组的临床效果及用药安全性。结果观察组疾病控制率为74.0%,对照组疾病控制率64.0%,差异无统计学意义（P〉0.05）;两组白细胞减少、粒细胞减少发生率差异有统计学意义（P〈0.05）,贫血血小板及胃肠道反应差异无统计学意义（P〉0.05）。结论培美曲塞及吉西他滨均有一定的临床效果且疗效简单,培美曲塞毒副作用较轻,应作为非小细胞肺癌治疗的首选方案。Objective To compare the clinical effect of pemetrexed and gemcitabine combined with nedaplatin in treatment of advanced non small cell lung cancer （NSCLC）. Methods 100 patients with lung adenocarcinoma in our hospital from July 2011 to August 2013 were randomly divided into observation group and control group,50 cases in each group, observation group were given with pemetrexed ＋ nedaplatin,control group were given with gemcitabine ＋ nedaplatin,the clinical efficacy and drug safety was compared between two groups. Results The disease control rate of observation group was 74%,the control group was 64%,the difference was not significant （P〉0.05）;the incidence of leukopenia and neutropenia between two groups had significant difference （P〈0.05）,anemia platelet and gastrointestinal reaction rate had no significant difference （P〈0.05）. Conclusion Pemetrexed and gemeitabine has certain clinical effeet,pemetrexed with low toxicity,can used as preferred scheme therapy of non-small cell lung cancer.

关 键 词：培美曲塞 吉西他滨 奈达铂 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]